PLEASE NOTE : This is a development system.
For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
You are here : Home > PAD Profile : Dexamethasone - Uveitis
PAD Profile : Dexamethasone - Uveitis Important
Keywords :
non-infectious uveitis
Brand Names Include :
Ozurdex
Important Information :
Ophthalmology specialists only
Traffic Light Status
Status 1 of 1.
Guidelines
No guidelines returned.
Other Drugs
- Bevacizumab
- Infliximab
- Atropine sulfate
- Fluocinolone acetonide
- Ciclosporin
- Methotrexate
- Azathioprine
- Mycophenolate mofetil
- Homatropine hydrobromide
Other Indications
- Retinal Vein Occlusion
- Diabetic macular oedema
- Eye inflammation
- Eye inflammation and bacterial infection
- Eye inflammation and bacterial infection
- Ocular surgery
- Nausea and vomiting (chemotherapy induced)
- Nausea and vomiting (post operative)
Additional Documents
Type
Document
Review Date
NICE Technology Appraisal
Committee Recommendations
Date
Committee Name
Narrative
04 October 2017
Surrey & North West Sussex Area Prescribing Committee (formerly Prescribing Clinical Network)
The PCN recommends Intravitreal dexamethasone implant (Ozurdex) for the treatment of non-infectious Uveitis in line with NICE TA460
Ozurdex is a payment by results excluded drug and will be considered RED on the traffic light system with treatment being provided by ophthalmology specialist teams in secondary care.
Specialists will be expected to notify commissioners through blueteq by completing tick box proformas for initiation and repeat implants.
Associated BNF Codes
11. Eye
11.04.01. Corticosteroids